In the first part of our analysis on the public biopharmaceutical companies presenting data at the ASCO meeting, covering the week the conference abstracts were released (May 11 - 15), we discovered that overall those abstract data did help improve company stock valuations, and, as a group, an average 3.2 percent increase in share price was recorded.